| Field | Specification |
|---|---|
| Target | |
| Alternative names | Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial; Protein SITPEC; ECSIT |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human ECSIT recombinant protein (Position: E83-S339). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial (gene ECSIT) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 49.1 kDa, and the supplier reports an observed band at about 49 kDa.
ECSIT is an adapter protein that helps connect TRAF6 and TAK1 to NF-κB activation in Toll-like receptor and IL-1 signaling. It is also found in mitochondria, where it assists assembly of respiratory complex I, so it is studied at the interface of innate immunity and mitochondrial function.
| Target | Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial (gene ECSIT; UniProt Q9BQ95, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 49.1 kDa |
| Observed MW | 49 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human PC-3 cells, human HeLa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human bladder adenosquamous carcinoma tissue, human colonic adenocarcinoma tissue, human gastric adenocarcinoma tissue, human liver cancer tissue, human lymphadenoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): PC-3 cells.
Samples with a confirmed signal (flow cytometry): HepG2 cells.
Immunogen
Recombinant human ECSIT fragment (Glu83–Ser339), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial in the cytoplasm, nucleus and mitochondrion. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
